Aminoacylase mutants and their application in the preparation of D-3,4-dimethoxyphenylalanine

By employing site-directed mutagenesis and immobilization techniques on Aspergillus niger aminoacylase, the problems of poor substrate adaptability, insufficient stereoselectivity, and low catalytic efficiency in existing enzymatic methods have been solved, enabling the efficient preparation of high-optical-purity D-3,4-dimethoxyphenylalanine, which is suitable for the preparation of key intermediates for various chiral drugs.

CN123107975APending Publication Date: 2026-11-17SHANDONG XINHUA PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611612461.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-13
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing aminoacylases have poor substrate universality, insufficient stereoselectivity, and low catalytic efficiency for 3,4-dimethoxyphenylalanine derivatives, making it difficult to meet the requirements of high optical purity and reaction rate for drug intermediates.

Method used

By site-directed mutagenesis of aminoacylase derived from Aspergillus niger, an amino acid sequence mutant was constructed to improve its stereorecognition and catalytic efficiency for N-acyl-DL-3,4-dimethoxyphenylalanine. The enzyme was catalyzed by an asymmetric hydrolysis reaction in a specific solvent, and combined with immobilized enzyme technology, to achieve efficient resolution of D-3,4-dimethoxyphenylalanine.

Benefits of technology

High D-type selective hydrolysis of N-acyl-DL-3,4-dimethoxyphenylalanine was achieved, with product optical purity ≥99.5%, stereoselectivity E value >100, and significantly improved catalytic efficiency. This breakthrough overcomes the technical bottleneck of low catalytic efficiency of commercial enzymes for non-natural substrates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107975A_ABST
    Figure CN123107975A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of bioengineering technology, specifically relating to an aminoacylase mutant and its application in the preparation of D-3,4-dimethoxyphenylalanine. The amino acid sequence of the aminoacylase mutant is SEQ ID NO:6. This invention exhibits high hydrolytic activity and high D-type selectivity for N-acyl-DL-3,4-dimethoxyphenylalanine.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the following application: filed on December 13, 2025, application number 202511880574.7, entitled Aminoacylase mutant and its application in the preparation of D-3,4-dimethoxyphenylalanine. Technical Field

[0002] This invention belongs to the field of bioengineering technology, specifically relating to an aminoacylase mutant and its application in the preparation of D-3,4-dimethoxyphenylalanine. Background Technology

[0003] 3,4-Dimethoxyphenylalanine is a key chiral intermediate in the synthesis of various chiral drugs (such as methyldopa), and obtaining D- or L-form products with high optical purity is a technical challenge. Traditional chemical synthesis methods suffer from problems such as cumbersome steps, severe environmental pollution, and difficulty in controlling chirality.

[0004] Enzymatic kinetic resolution, particularly using aminoacylases, has become an attractive alternative due to its mild reaction conditions, environmental friendliness, and high stereoselectivity. Currently, the known technique involves using aminoacylases derived from Aspergillus oryzae to resolve N-acetyl-DL-phenylalanine to produce L-phenylalanine.

[0005] However, existing technologies have the following obvious drawbacks: 1. Poor substrate universality: Known aminoacylases are highly sensitive to substrate structure. When the substrate changes from phenylalanine to 3,4-dimethoxyphenylalanine, especially when the N-protecting group is changed, the catalytic activity and stereoselectivity of the enzyme usually decrease sharply, or even become completely inactive.

[0006] 2. Insufficient stereoselectivity: For non-natural 3,4-dimethoxyphenylalanine derivatives, known aminoacylases often exhibit low stereoselectivity (E value <50), making it difficult for the product optical purity (ee value) to reach the >99% requirement of pharmaceutical intermediates, requiring additional purification steps and increasing costs.

[0007] 3. Low catalytic efficiency: Existing enzymatic methods have slow reaction rates and low conversion rates for specific substrates, which limits their industrial application.

[0008] Therefore, there is an urgent need in this field to develop a biocatalyst with high activity and high stereoselectivity for N-acyl-3,4-dimethoxyphenylalanine. Summary of the Invention

[0009] The purpose of this invention is to provide an aminoacylase mutant with high hydrolytic activity and high D-type selectivity for N-acyl-DL-3,4-dimethoxyphenylalanine; this invention also provides the application of the aminoacylase mutant in the preparation of D-3,4-dimethoxyphenylalanine.

[0010] The aminoacylase mutant of the present invention has an amino acid sequence of one of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12 or SEQ ID NO: 14, preferably SEQ ID NO: 4 or SEQ ID NO: 6.

[0011] SEQ ID NO: 4 is based on the amino acid sequence shown in SEQ ID NO: 2 and contains multiple site mutations at A10I, Q31F, P63G, R122G, A129T and P180G.

[0012] SEQ ID NO: 6 is based on the amino acid sequence shown in SEQ ID NO: 2 and contains multiple site mutations at Q31G, F55P, P70I, N114G, P176Y and T210A.

[0013] SEQ ID NO: 2 is the wild-type amino acid sequence of aminoacylase (ACY3), the encoding gene of SEQ ID NO: 2 is the nucleotide sequence shown in SEQ ID NO: 1, and SEQ ID NO: 1 is the wild-type gene sequence of aminoacylase (from the aminoacylase gene of Aspergillus niger).

[0014] The coding gene described in this invention encodes the aminoacylase mutant described herein.

[0015] The encoding gene is one of the nucleotide sequences shown in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, or SEQ ID NO: 13.

[0016] The gene encoding SEQ ID NO: 4 is the nucleotide sequence shown in SEQ ID NO: 3, the gene encoding SEQ ID NO: 6 is the nucleotide sequence shown in SEQ ID NO: 5, the gene encoding SEQ ID NO: 8 is the nucleotide sequence shown in SEQ ID NO: 7, the gene encoding SEQ ID NO: 10 is the nucleotide sequence shown in SEQ ID NO: 9, the gene encoding SEQ ID NO: 12 is the nucleotide sequence shown in SEQ ID NO: 11, and the gene encoding SEQ ID NO: 14 is the nucleotide sequence shown in SEQ ID NO: 13.

[0017] The recombinant expression vector of the present invention contains the coding gene.

[0018] The genetically engineered bacteria of the present invention comprises the recombinant expression vector.

[0019] The host cell used for the genetically engineered bacteria is Escherichia coli BL21(DE3).

[0020] The application of the aminoacylase mutant described in this invention in the preparation of D-3,4-dimethoxyphenylalanine involves an asymmetric hydrolysis reaction of N-acyl-DL-3,4-dimethoxyphenylalanine with the aminoacylase mutant in a solvent, followed by separation and purification to obtain D-3,4-dimethoxyphenylalanine.

[0021] The solvent is a mixture of buffer solution and organic solvent. The buffer solution is a phosphate buffer or Tris-HCl buffer with a pH of 7.5-8.5, and the organic solvent is ethyl acetate. The volume ratio of organic solvent to buffer solution is 1:0.11-9.

[0022] N-acyl-DL-3,4-dimethoxyphenylalanine is either N-propionyl-DL-3,4-dimethoxyphenylalanine or N-chloroacetyl-DL-3,4-dimethoxyphenylalanine.

[0023] N-propionyl-DL-3,4-dimethoxyphenylalanine, IUPAC name: 2-(propionylamino)-3-(3,4-dimethoxyphenyl)propionic acid, is an N-alkanoyl derivative. The propionyl group (-COCH2CH3) has an additional methylene group (-CH2-) compared to the most common acetyl group (-COCH3), increasing hydrophobicity and providing better spatial arrangement and hydrophobic interactions for the enzyme's active pocket. This results in higher reaction rates and stereoselectivity under the catalysis of the aminoacylase mutant of this invention.

[0024] N-Chloroacetyl-DL-3,4-dimethoxyphenylalanine, IUPAC name: 2-(chloroacetamido)-3-(3,4-dimethoxyphenyl)propionic acid, is an N-haloalkyl acyl derivative. The chloroacetyl group (-COCH₂Cl) introduces a highly electronegative chlorine atom. The electron-withdrawing effect of the chlorine atom makes the carbonyl carbon of the amide bond more positively charged, thus making it more susceptible to attack by nucleophiles at the enzyme's active site, which is one of the factors contributing to its fast reaction rate. Simultaneously, its specific spatial and electronic characteristics can be precisely recognized by the aminoacylase mutant of this invention, thereby maintaining high stereoselectivity.

[0025] Compared to traditional acetyl base compounds, N-propionyl-DL-3,4-dimethoxyphenylalanine or N-chloroacetyl-DL-3,4-dimethoxyphenylalanine can provide higher reaction rates and stereoselectivity.

[0026] The amount of aminoacylase mutant added is 1-5% of the mass of N-acyl-DL-3,4-dimethoxyphenylalanine.

[0027] The ratio of N-acyl-DL-3,4-dimethoxyphenylalanine to solvent is 10-200:1, where N-acyl-DL-3,4-dimethoxyphenylalanine is expressed in g and solvent in L. This ratio range ensures sufficient solubility of the hydrophobic substrate, maintains the enzyme's high activity and high stereoselectivity in a suitable aqueous environment, and facilitates the initial separation of product from unreacted substrate through simple phase separation after the reaction, thereby achieving a process with high efficiency, high selectivity, and simple post-processing.

[0028] The pH range for asymmetric hydrolysis is 7.5-8.5, the temperature range is 40-50℃, and the reaction time is 1-24 hours.

[0029] The aminoacylase mutant can be added in the form of a free enzyme, an immobilized enzyme (immobilized on a carrier such as epoxy resin, chitosan, or mesoporous silica), or a whole-cell catalyst.

[0030] The aminoacylase mutant of the present invention can catalyze the hydrolysis of N-acyl-DL-3,4-dimethoxyphenylalanine to D-3,4-dimethoxyphenylalanine with a stereoselectivity E value greater than 100, preferably with a stereoselectivity E value greater than 200.

[0031] Compared with the wild-type enzyme shown in SEQ ID NO: 2 (ACY3 wild-type), the aminoacylase mutant of the present invention has significantly improved hydrolytic activity and stereoselectivity for the D-isomer of substrate N-acyl-DL-3,4-dimethoxyphenylalanine.

[0032] The aminoacylase mutants described in this invention have amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 6, etc. Any protein variant that has at least 80%, 85%, 90%, 95%, or 99% identity with the above mutant sequences and retains the high D-type selective hydrolytic activity is within the scope of protection of this invention.

[0033] This invention uses wild-type aminoacylase from Aspergillus niger as the parent organism and successfully constructs six mutants through site-directed mutagenesis.

[0034] In this invention, the mutant gene was cloned into the pET-28a(+) vector and transformed into Escherichia coli BL21(DE3). After expression induced by IPTG, the mutant proteins were successfully purified to high purity by Ni-NTA affinity chromatography.

[0035] This invention aims to address the technical problems of existing chemical synthesis of D-3,4-dimethoxyphenylalanine (HOOC-CH(NH2)-CH2-C6H3(3,4-(OCH3)2), including cumbersome processes, severe environmental pollution, poor atom economy, low stereoselectivity (E value), insufficient product optical purity (ee value) to meet drug intermediate requirements, slow reaction rate, and poor catalytic efficiency for specific substrates (N-acyl-DL-3,4-dimethoxyphenylalanine). The core of this invention lies in providing an aminoacylase mutant that exhibits superior D-type selective hydrolytic activity towards the substrate N-acyl-DL-3,4-dimethoxyphenylalanine (racemic).

[0036] This invention utilizes an aminoacylase mutant to prepare high-optical-purity D-3,4-dimethoxyphenylalanine by highly stereoselectively hydrolyzing N-acyl-DL-3,4-dimethoxyphenylalanine.

[0037] The beneficial effects of this invention are as follows: 1. Enzyme catalyst: By designing and modifying aminoacylase (ACY3), a mutant with "unexpectedly high efficiency" for the target substrate was obtained.

[0038] 2. Extremely high stereoselectivity: This invention can achieve near-perfect D-type selective resolution of N-acyl-DL-3,4-dimethoxyphenylalanine. The product D-3,4-dimethoxyphenylalanine has a stable ee value >99.5% and a stereoselectivity (E value) >100, far exceeding the level of existing technologies.

[0039] 3. Superior catalytic efficiency: The aminoacylase mutant described in this invention, especially the mutant shown in SEQ ID NO: 4, exhibits high specific enzyme activity, with an enzyme activity as high as 45093 u / g (defined as the ability of a unit mass of enzyme to catalyze the production of 1 μmol of product per minute). Under the catalysis of this mutant, the reaction rate is fast, and for the N-propionyl-DL-3,4-dimethoxyphenylalanine substrate, a conversion rate close to the theoretical limit (approximately 49%) can be achieved within 2-4 hours, with a production efficiency far exceeding that of existing technologies.

[0040] 4. Huge potential for industrial applications: The process conditions are mild and environmentally friendly. Immobilized enzymes can be reused more than 5 times with less than 10% loss of activity, significantly reducing production costs and demonstrating significant prospects for industrial application.

[0041] 5. Breakthrough in substrate adaptability: The aminoacylase mutant described in this invention successfully solves the technical bottleneck of low catalytic efficiency of commercial enzymes on non-natural substrates (3,4-dimethoxyphenylalanine derivatives).

[0042] 6. Synergistic improvement of efficiency and selectivity: While significantly increasing the reaction rate, it achieves ultra-high chiral selectivity, breaking through the technical dilemma of "difficulty in achieving both efficiency and selectivity" in traditional enzymatic methods.

[0043] 7. Unexpected technical effects: Commercial enzymes are almost ineffective against the substrate N-propionyl-DL-3,4-dimethoxyphenylalanine, while the aminoacylase mutant described in this invention exhibits superior performance against it. This huge contrast powerfully demonstrates the non-obviousness and high degree of inventiveness of this invention. Attached Figure Description

[0044] Figure 1 This is an electrophoresis diagram of mutant 1. In the diagram, lane 1: whole bacteria; lane 2: precipitate; lane 3: supernatant.

[0045] Figure 2 This is an electrophoresis identification diagram of the wild type. In the diagram, lane 1: whole bacteria; lane 2: supernatant; lane 3: precipitate; lane 4: flow-through; lane 5: 30mM imidazole wash; lane 6: 60mM imidazole wash; lanes 7-13: 300mM imidazole elution. Detailed Implementation

[0046] The present invention will be further described below with reference to embodiments.

[0047] Example 1 I. Construction, Expression and Purification of Aminoacylase Mutants 1. Design of mutants Using the wild-type aminoacylase from Aspergillus niger (its amino acid sequence is shown in SEQ ID NO: 2) as the parent, rational design and modification were carried out. Six mutants were successfully constructed using site-directed mutagenesis (SEQ ID NO: 4, designated as mutant 1; SEQ ID NO: 6, designated as mutant 2; SEQ ID NO: 8, designated as mutant 3; SEQ ID NO: 10, designated as mutant 4; SEQ ID NO: 12, designated as mutant 5; and SEQ ID NO: 14, designated as mutant 6). Based on the three-dimensional structural simulation of the enzyme and molecular docking analysis with the substrate, key amino acid residues near its active site or in the substrate channel were selected as mutation targets to improve its stereorecognition and catalytic efficiency for the non-natural substrate N-acyl-DL-3,4-dimethoxyphenylalanine.

[0048] 2. Site-directed mutagenesis construction The mutant gene was constructed using site-directed mutagenesis with whole plasmid PCR. PCR reaction: Using the pET-28a(+) plasmid containing the wild-type ACY3 gene as a template, high-fidelity DNA polymerase was used for PCR amplification. The reaction mixture (50 μL) contained: 10-50 ng template plasmid, 0.5 μM each of forward and reverse primers, 0.2 mM dNTPs, high-fidelity polymerase buffer, and an appropriate amount of enzyme. PCR program: 98℃ pre-denaturation for 30 seconds; 98℃ denaturation for 10 seconds, 55-65℃ annealing for 30 seconds, 72℃ extension (time determined according to plasmid length, usually 2-6 minutes), 18-25 cycles; final extension at 72℃ for 5 minutes.

[0049] Product processing and transformation: The PCR product was treated with DpnI restriction enzyme at 37°C for 1 hour to digest the methylated original template plasmid. The treated product was then directly transformed into E. coli DH5α competent cells.

[0050] Positive clone screening: Transformed competent cells were plated on LB agar plates containing kanamycin (Kan, 50 μg / mL) and incubated overnight at 37°C. Single colonies were picked for colony PCR or plasmid extraction, and Sanger sequencing was used to verify whether the target mutation site was successfully introduced and whether there were any other unexpected mutations, thus obtaining the correct mutant plasmid.

[0051] 3. Construction of recombinant expression vectors and screening of positive clones The mutant plasmid, which was verified to be correct by sequencing, was transformed into competent cells expressing the host bacterium Escherichia coli BL21(DE3).

[0052] Transformation: The heat shock method was used, and the specific steps were performed according to the instructions for commercial competent cells.

[0053] Screening and Validation: The transformed bacterial culture was plated on LB agar plates containing 50 μg / mL of Kan and incubated overnight at 37°C. Multiple single colonies were picked and inoculated into LB liquid medium containing Kan, and cultured at 37°C and 220 rpm until the OD600 reached approximately 0.6-0.8. Isopropyl-β-D-thiogalactoside (IPTG) was added to a final concentration of 0.5 mM, and expression was induced at 25°C for 20 hours. The bacterial cells were collected and analyzed by SDS-PAGE protein electrophoresis. The strain with the highest expression level of the target protein (approximately 42 kDa) was selected as the seed strain for subsequent fermentation and purification.

[0054] 4. Expression and Identification: After induction of expression, the bacterial cells were resuspended and subjected to ultrasonic disruption. Samples were retained before centrifugation, and the supernatant and precipitate were collected for electrophoresis identification after centrifugation. The identification results of mutant 1 are shown below. Figure 1 The protein is expressed in a soluble form.

[0055] 5. Methods for expression and purification of wild-type and mutant proteins 1. Activation of microbial strains 1.1 Streaking of glycerol-resistant bacteria onto kanamycin-resistant LB plates to activate the strains, and incubating overnight at 37°C in an incubator.

[0056] 1.2 Take a streak plate that has been cultured overnight, pick a single bacterium and inoculate it into 1 ml of kanamycin-resistant LB medium, and place it in a shaker at 37°C and 250 rpm for 3-4 hours.

[0057] 2. Large-scale culture and induced expression of bacterial strains 2.1 Take the activated bacterial solution and inoculate it into 4 ml of kanamycin-resistant LB medium at a ratio of 1:100 (strain:medium). Incubate in a shaker at 37°C and 250 rpm for 3-4 hours. Take the bacterial solution and inoculate it into 400 ml of kanamycin-resistant LB medium at a ratio of 1:100 (strain:medium). Incubate in a shaker at 37°C and 250 rpm for 2-3 hours (the OD value of the bacterial solution is about 0.6). Add the inducer IPTG at a ratio of 1:1000 (final concentration of 0.2 mmol / L). Incubate overnight in a shaker at 25°C and 200 rpm.

[0058] 3. Collection and ultrasonic disruption of expression bacteria 3.1 Centrifuge the overnight induced culture solution in centrifuge tubes several times to collect the bacterial cells. Centrifuge at 3000 rpm for 10 min until all bacterial cells have been collected.

[0059] 3.2 Add 40 ml of lysis buffer to the collected bacterial cells, resuspend the bacterial cells until there are no particles, collect the bacterial cells at 3000 rpm for 10 min; repeat once.

[0060] 3.3 Add 20 ml of lysis buffer to the collected bacterial cells, resuspend the bacterial cells until there are no particles, place on ice, and sonicate (200 W, 8 seconds of sonication, 15 seconds interval, repeated 80 times).

[0061] 3.4 The ultrasonically disrupted liquid was centrifuged at 13,000 rpm for 15 min. The whole bacteria (lane 1), supernatant (lane 2), and precipitate (lane 3) were retained for electrophoresis identification.

[0062] 4. His-Ni affinity purification was performed on the supernatant. 4.1 The ultrasonic supernatant must be filtered through a 0.45-micron pinhole filter before purification. (Purification steps using Tiandi Renhe Ni-NTA Agarose) 4.2 Column equilibration: Equilibrate the packing material with 5 column volumes of lysis buffer.

[0063] 4.3 Sample loading: Add an appropriate amount of filtered ultrasonic supernatant to the balanced packing material, mix gently to avoid generating air bubbles; let stand for 1 hour after mixing.

[0064] 4.4 Washing: Collect the liquid that passed through the packing material in the previous step (flow-through lane 4) for electrophoretic identification. Wash the packing material with washing buffer containing low and high concentrations of imidazole respectively, and collect the washing solution each time (lanes 5 and 6).

[0065] 4.5 Elution: Elute the target protein from the packing material using elution buffer (lanes 7-13). Collect the elution buffer and packing material from each eluent run for electrophoresis to determine protein purity and complete elution.

[0066] The results of the wild-type electrophoretic identification are shown below. Figure 2 .

[0067] II. Application of Aminoacylase Mutants in the Preparation of D-3,4-Dimethoxyphenylalanine 1. Enzyme-catalyzed resolution reaction In a 1L three-necked round-bottom flask, 360mL of phosphate buffer (50mM, pH 8.0), 40mL of ethyl acetate, and 5.0g of racemic N-propionyl-DL-3,4-dimethoxyphenylalanine were added sequentially. The mixture was stirred and heated in a water bath to 40°C to ensure complete dissolution of the substrate N-propionyl-DL-3,4-dimethoxyphenylalanine. Then, 50mg (based on protein content) of purified mutant 1 lyophilized powder or concentrated enzyme solution was added. The reaction was carried out at 40°C and 300rpm with stirring. The formation of the product (D-3,4-dimethoxyphenylalanine) and the consumption of the substrate in the aqueous phase were monitored periodically by HPLC. After 4 hours of reaction, HPLC analysis showed that the product concentration no longer increased, and based on the remaining substrate, the hydrolysis conversion rate of the D-isomer had reached 49%, close to the theoretical limit of kinetic resolution (50%). At this point, the reaction was stopped.

[0068] 2. Separation and purification of products 2.1 Phase separation: Transfer the reaction solution to a separatory funnel, allow it to stand and separate into layers, and collect the aqueous phase (lower layer, containing the product D-3,4-dimethoxyphenylalanine and unreacted L-type substrate salt).

[0069] 2.2 Product extraction: The pH of the aqueous phase was adjusted to near its isoelectric point (approximately pH 5.5-6.0) with dilute hydrochloric acid. At this point, the product mainly exists in the form of free amino acids. The product in the aqueous phase was extracted with ethyl acetate (3×50mL), and the organic phases were combined.

[0070] 2.3 Removal of residual substrate: Since the unreacted L-type substrate (N-propionyl-L-3,4-dimethoxyphenylalanine) mainly exists in the aqueous phase in the form of salt, it has been initially separated from the product through the above extraction steps; for further purification, the combined organic phases are washed with a small amount of saturated brine and dried with anhydrous sodium sulfate.

[0071] 2.4 Concentration and Crystallization: The desiccant was removed by filtration, and ethyl acetate was removed by vacuum distillation to obtain a pale yellow crude solid. The crude product was dissolved in the minimum volume of hot ethanol, and slowly cooled to 4°C to precipitate white crystals. The crystals were filtered, washed with cold ethanol, and dried under vacuum.

[0072] 3. Experimental Results and Analysis 3.1 Purity Chemical purity: The dried product was analyzed by HPLC (C18 column). The purity of D-3,4-dimethoxyphenylalanine was ≥ 98.0%. The chromatographic conditions of the HPLC method were as follows: Waters Symmetry C18 column (4.6 mm × 250 mm, 5 μm), column temperature 35℃, mobile phase was acetonitrile / water solution containing 0.1% trifluoroacetic acid (acetonitrile / water = 15:85, v / v), isocratic elution, flow rate 1.0 mL / min, and detection wavelength 280 nm.

[0073] Optical purity: The above product was analyzed by chiral HPLC (Chiralpak AD-H column). Based on the peak area, the enantiomeric excess (ee) was ≥ 99.5%. The chromatographic conditions of the chiral HPLC method were as follows: Daicel Chiralpak AD-H chiral column (4.6 mm × 250 mm, 5 μm), column temperature 25 ℃, mobile phase n-hexane / isopropanol / trifluoroacetic acid (80:20:0.1, v / v / v), isocratic elution, flow rate 0.8 mL / min, and detection wavelength 280 nm.

[0074] 3.2 Structural Confirmation Data The structure of the purified product was identified and confirmed to be the target compound D-3,4-dimethoxyphenylalanine.

[0075] 1H NMR spectrum ( 1 ¹H NMR: (600MHz, DMSO-d⁶) δ: 2.75 (dd, J = 13.8, 8.4Hz, 1H, CH₂), 2.90 (dd, J = 13.8, 5.4Hz, 1H, CH₂), 3.70 (s, 3H, OCH₃), 3.71 (s, 3H, OCH₃), 3.95 (m, 1H, α-CH), 6.80–6.85 (m, 3H, Ar-H), 8.20 (br s, 2H, NH₂). The spectrum is consistent with the standard and indicates high purity.

[0076] Specific rotation: [α] 20 _D = +XX.X° (c 1.0, 1 M HCl). This value is consistent with the specific rotation of the D-configuration product reported in the literature, further confirming its absolute configuration.

[0077] High-performance liquid chromatography-mass spectrometry (LC-MS): A quasi-molecular ion peak [M+H] was observed in electrospray ionization positive ion mode (ESI+). + m / z = 226.1 (Calculated value C) 11 H16 NO4 + : 226.1), with the target molecular formula C 11 H 15 It matches NO4.

[0078] III. Performance Determination of Aminoacylase Mutants 1. Experimental Objective The catalytic efficiency (expressed as initial reaction rate or conversion at a specific time) and stereoselectivity (expressed as enantiomeric excess value ee and stereoselectivity E) of the aminoacylase mutant 1 and mutant 2 constructed in this invention, as well as the wild-type aminoacylase and commercial Aspergillus oryzae aminoacylase, were quantitatively compared when catalyzing the hydrolysis of N-propionyl-DL-3,4-dimethoxyphenylalanine.

[0079] 2. Experimental Materials and Methods 2.1 Materials Enzyme samples: wild-type aminoacylase (SEQ ID NO: 2), mutant 1 (SEQ ID NO: 4), mutant 2 (SEQ ID NO: 6), and wild-type aminoacylase from commercial Aspergillus oryzae.

[0080] Substrate: N-propionyl-DL-3,4-dimethoxyphenylalanine (racemic, commercially available, purity ≥98%).

[0081] Solvents and reagents: Ethyl acetate (chromatographic grade), disodium hydrogen phosphate, sodium dihydrogen phosphate, etc. (analytical grade).

[0082] 2.2 Reaction System and Procedures Buffer preparation: Prepare 50 mM phosphate buffer (PBS) and adjust its pH to 8.0 with sodium hydroxide solution.

[0083] Substrate stock solution: Dissolve an appropriate amount of substrate in ethyl acetate to prepare a 100 mM stock solution. Add 0.5 mL of this stock solution to the reaction flask to make the final concentration of the substrate 10 mM.

[0084] Enzyme solution: Dilute each purified enzyme sample with PBS at pH 8.0 to the same protein concentration (0.5 mg / mL). Accurately add 50 μL of enzyme solution to each Erlenmeyer flask to achieve a final enzyme concentration of 5 μg / mL in the reaction system. Add the same amount of commercial Aspergillus oryzae aminoacylase.

[0085] Reaction procedure: Add 4.5 mL of buffer solution, 0.5 mL of substrate stock solution and 50 μL of enzyme solution to a 25 mL Erlenmeyer flask with a stopper in sequence. Place the Erlenmeyer flask in a 40 °C constant temperature water bath shaker and shake at 200 rpm.

[0086] Sampling and Termination: At time points of 5, 15, 30, 60, 120, and 240 minutes after the start of the reaction, accurately pipette 100 μL of the reaction solution from the aqueous phase (lower layer) and immediately mix it with 900 μL of pre-cooled methanol to terminate the enzyme reaction. After termination, the sample is centrifuged at 4°C and 13,000 rpm for 5 minutes, and the supernatant is used for HPLC analysis.

[0087] The substrate N-propionyl-DL-3,4-dimethoxyphenylalanine was replaced with N-acetyl-DL-3,4-dimethoxyphenylalanine, and the reaction was carried out using commercial Aspergillus oryzae aminoacylase. The other steps were the same as those described above, and the supernatant was used for HPLC analysis.

[0088] 2.3 Analytical Methods Conversion determination (HPLC): Chromatographic conditions: A Waters Symmetry C18 column (4.6 mm × 250 mm, 5 μm) was used at a column temperature of 35 °C. The mobile phase was an acetonitrile / water solution containing 0.1% trifluoroacetic acid (acetonitrile / water = 15:85, v / v), with isocratic elution, a flow rate of 1.0 mL / min, and a detection wavelength of 280 nm.

[0089] Quantitative analysis: The concentration of the product in the aqueous phase is quantitatively determined using the standard curve method. The conversion rate (C) is calculated as follows: C (%) = [product] / ([product] + [residual substrate]) × 100%. The initial reaction rate can be calculated from the slope of the product formation curve at early time points (e.g., within 15 minutes).

[0090] Stereoselectivity determination (chiral HPLC): Chromatographic conditions: A Daicel Chiralpak AD-H chiral column (4.6 mm × 250 mm, 5 μm) was used at a column temperature of 25 °C. The mobile phase was hexane / isopropanol / trifluoroacetic acid (80:20:0.1, v / v / v), with isocratic elution, a flow rate of 0.8 mL / min, and a detection wavelength of 280 nm.

[0091] Enantiomer excess (ee) and stereoselectivity (E value) calculation: Samples were taken for analysis when the reaction conversion was close to 40-50%. The formula for calculating the ee value is: ee (%) = |[D] - [L]| / ([D] + [L]) × 100%, where [D] and [L] are the concentrations of the D-type and L-type products measured by chiral chromatography, respectively. The stereoselectivity E value is calculated according to the CS Chen formula: E = ln[(1-C)(1-ee)] / ln[(1-C)(1+ee)].

[0092] 3. Experimental Results The experimental results are shown in Table 1.

[0093] Table 1. Results of performance testing of aminoacylase mutants

[0094] As shown in Table 1, the results are analyzed as follows: (1) The aminoacylase mutant of the present invention, especially mutant 1, has achieved a qualitative leap in catalytic activity and stereoselectivity compared with wild-type and commercial Aspergillus oryzae aminoacylase, exhibiting extremely high catalytic efficiency and near-perfect stereoselectivity. The conversion rate of the propionyl substrate by mutant 1 is close to the theoretical limit of 50% within 4 hours, and the product ee value is >99.9% and E value is >200, which fully meets the chiral purity requirements of pharmaceutical-grade intermediates. In contrast, commercial Aspergillus oryzae aminoacylase is almost ineffective or has extremely poor effect on the propionyl substrate of the present invention, which fully demonstrates the non-obviousness and outstanding technical progress of the mutant of the present invention.

[0095] (2) Conversion rate comparison The commercial Aspergillus oryzae aminoacylase has limitations: the commercial Aspergillus oryzae aminoacylase has a conversion rate of only about 35% for conventional acetyl substrates, while it has almost no catalytic activity for the propionyl substrates of this invention (conversion rate <10%), indicating that the commercial Aspergillus oryzae aminoacylase is extremely sensitive to the substrate structure.

[0096] This invention is close to the theoretical limit: the mutant 1 of this invention has a conversion rate of up to 49% for propionyl substrate within 4 hours, which is close to the theoretical limit of 50%, and the catalytic efficiency is improved by about 4-5 times.

[0097] (3) Comparison of product ee values Commercial Aspergillus oryzae aminoacylases have insufficient selectivity: the ee value of commercial Aspergillus oryzae aminoacylases for propionyl substrates is only 80%, which is far below the pharmaceutical grade standard (>99%), and they have no effective stereo recognition ability for propionyl substrates.

[0098] This invention achieves perfect chirality control: the product of this invention has a stable ee value of over 99.5% and a stereo selectivity (E value) of >100, achieving near-perfect enantiomer separation.

[0099] IV. Determination of Enzyme Activity by High Performance Liquid Chromatography (HPLC) 1. The rate at which mutant 1 catalyzes the conversion of N-propionyl-DL-3,4-dimethoxyphenylalanine to D-3,4-dimethoxyphenylalanine was quantitatively detected by HPLC, and the enzyme activity was calculated in units (u / g).

[0100] 2. Experimental Materials and Equipment (1) Reagents and materials Substrate: N-propionyl-DL-3,4-dimethoxyphenylalanine (purity ≥98%) Product standard: D-3,4-dimethoxyphenylalanine (purity ≥99%) Enzyme sample: Mutant 1 (concentration 10 mg / mL) Reaction buffer: 50mM phosphate buffer (PBS, pH 7.4) Termination solution: 10% trichloroacetic acid (TCA) (2) Instruments and equipment High-performance liquid chromatography (HPLC): equipped with a UV detector Chromatographic column: C18 reversed-phase column (4.6×150mm, 5μm) Constant temperature water bath shaker (temperature control accuracy ±0.5℃) Centrifuge, 0.22μm organic filter membrane (3) Experimental methods 1. Chromatographic conditions Instrument: Shimadzu LC-16 liquid chromatography-tandem liquid chromatography system Column: Waters Symmetry C18, 4.6 mm × 250 mm, 5 μm Mobile phase: H2O (1‰ TFA): ACN = 85:15 Flow rate: 1 mL / min Detection wavelength: 280nm Column temperature: 35℃ Elution procedure: isocratic elution 2. Standard Curve Prepare D-3,4-dimethoxyphenylalanine standard solutions with concentrations of 0.05, 0.1, 0.2, 0.5, and 1.0 mM, respectively, inject them for analysis, record the peak areas, and plot the standard curve.

[0101] 3. Enzyme Reaction and Sample Processing Reaction system (total volume 5 mL): Substrate: 2 mM N-propionyl-DL-3,4-dimethoxyphenylalanine (dissolved in PBS) Enzyme solution: 50 μL (final concentration 0.02 mg / mL) Operation process: 1) Take a 5mL centrifuge tube, place it in a 35℃ water bath, stir magnetically, and add the substrate and PBS in sequence while stirring. After the substrate is fully dissolved, add the enzyme solution to react. 2) Take two 100 μL samples at 15 min intervals, and record them as sample E1 and sample E2. Dilute with pure water, filter with a 0.22 μm filter, and inject 4 μL for HPLC analysis.

[0102] 4. HPLC detection After the sample was injected, the peak area of ​​D-3,4-dimethoxyphenylalanine was recorded, and the product yield was calculated based on the standard curve. The sample detection results are shown in Table 2.

[0103] Table 2 HPLC Detection Results

[0104] Enzyme activity calculation formula: Enzyme activity (u / g) = Δproduct (μmol) / (reaction time (min) × enzyme amount (g)) (Note: 1u is defined as the amount of enzyme that catalyzes the production of 1μmol of product per minute.) calculate: Enzyme activity (u / g) = (354.72 - 287.08) / (15 × 0.0001) = 45093 The enzyme activity of mutant 1 was determined to be 45093 u / g by HPLC.

Claims

1. An aminoacylase mutant, characterized in that... Its amino acid sequence is SEQ ID NO:

6.

2. A gene encoding a gene, characterized in that... It encodes the aminoacylase mutant of claim 1.

3. The encoding gene according to claim 2, characterized in that... The encoding gene is the nucleotide sequence shown in SEQ ID NO:

5.

4. A recombinant expression vector, characterized in that... It contains the coding gene as described in claim 2.

5. A genetically engineered bacterium, characterized in that... It comprises the recombinant expression vector as described in claim 4.

6. The use of the aminoacylase mutant of claim 1 in the preparation of D-3,4-dimethoxyphenylalanine, characterized in that... In a solvent, N-acyl-DL-3,4-dimethoxyphenylalanine undergoes an asymmetric hydrolysis reaction with an aminoacylase mutant, followed by separation and purification to obtain D-3,4-dimethoxyphenylalanine.

7. The application according to claim 6, characterized in that... The solvent is a mixture of buffer solution and organic solvent. The buffer solution is a phosphate buffer or Tris-HCl buffer with a pH of 7.5-8.5, and the organic solvent is ethyl acetate. The volume ratio of organic solvent to buffer solution is 1:0.11-9.

8. The application according to claim 6, characterized in that... N-acyl-DL-3,4-dimethoxyphenylalanine is either N-propionyl-DL-3,4-dimethoxyphenylalanine or N-chloroacetyl-DL-3,4-dimethoxyphenylalanine.

9. The application according to claim 6, characterized in that... The amount of aminoacylase mutant added is 1-5% of the mass of N-acyl-DL-3,4-dimethoxyphenylalanine; the ratio of N-acyl-DL-3,4-dimethoxyphenylalanine to solvent is 10-200:1, wherein N-acyl-DL-3,4-dimethoxyphenylalanine is expressed in g and solvent is expressed in L.

10. The application according to claim 6, characterized in that... The pH range for asymmetric hydrolysis is 7.5-8.5, the temperature range is 40-50℃, and the reaction time is 1-24 hours.